Implications of the LIFE trial

Sunil Nadar, Hoong Lim, Gregory Lip

Research output: Contribution to journalReview article

8 Citations (Scopus)


The recent Losartan intervention For Endpoint Reduction in Hypertension (LIFE) study was conducted in patients with essential hypertension with electrocardiogram evidence of left ventricular hypertrophy. This showed that losartan compared to atenolol resulted in a significant reduction in the primary endpoint of cardiovascular morbidity and mortality, as well as a greater reduction in electrocardiographically-defined left ventricular hypertrophy. Importantly, this was despite a mean blood pressure reduction which was similar in both groups. Furthermore, the atenolol arm was associated with higher incidence of newly diagnosed diabetics. The LIFE study has firmly confirmed a place for losartan (and other angiotensin receptor blockers) in the management of hypertension. Losartan has also been shown to be effective in diabetics and in patients with atrial fibrillation, as well as in left ventricular hypertrophy regression. This trial also raises the possibility that beta-blockers should perhaps not be used as first-line monotherapy.
Original languageEnglish
Pages (from-to)871 -877
Number of pages8007
JournalExpert opinion on investigational drugs
Issue number5
Publication statusPublished - 1 May 2003


  • losartan
  • angiotensin receptor blockers
  • hypertension
  • cardiovascular mortality


Dive into the research topics of 'Implications of the LIFE trial'. Together they form a unique fingerprint.

Cite this